j 2022

Chronic Pancreatitis and Diabetes of Exocrine Pancreas / Type 3c Diabetes Mellitus / Post-pancreatitis Diabetes Mellitus

DÍTĚ, Petr, Martina BOJKOVÁ, Jana BĚLOBRÁDKOVÁ, Petr ŽÁK, Bohuslav KIANIČKA et. al.

Basic information

Original name

Chronic Pancreatitis and Diabetes of Exocrine Pancreas / Type 3c Diabetes Mellitus / Post-pancreatitis Diabetes Mellitus

Authors

DÍTĚ, Petr, Martina BOJKOVÁ, Jana BĚLOBRÁDKOVÁ, Petr ŽÁK and Bohuslav KIANIČKA

Edition

JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, ROMANIA, MEDICAL UNIV PRESS, 2022, 1841-8724

Other information

Language

English

Type of outcome

Článek v odborném periodiku (nerecenzovaný)

Field of Study

30219 Gastroenterology and hepatology

Country of publisher

Romania

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.100

Organization unit

Faculty of Medicine

Keywords in English

chronic pancreatitis; type 3c diabetes mellitus; post-pancreatitis diabetes mellitus
Změněno: 21/2/2023 08:56, Mgr. Tereza Miškechová

Abstract

V originále

In 2011 and subsequently in 2012, the American Diabetes Association (ADA), together with the WHO, defined a new type of diabetes in connection with the disease of the exocrine pancreas. For this type of diabetes, the term pancreatogenic diabetes was used, or type 3c diabetes mellitus (DM3c, T3cDM). So far, the terms secondary pancreatic diabetes and diabetes of the exocrine pancreas (DEP) – as a synonym for the two abovementioned terms – have still been used. In 2022, at the congress of the European Pancreatic Club another term appeared, namely post-pancreatitis DM (PPDM). Diabetes of the exocrine pancreas is characterized by exocrine and endocrine dysfunction of the pancreas, involving not only insulin secretion but also pancreatic polypeptide producing cells. In the current review, authors present the current knowledge about this increasingly prevalent disease.

Links

MUNI/A/1156/2021, interní kód MU
Name: Diferenciální diagnostika a odhad prognózy vnitřních nemocí 5 (Acronym: DIDIPRON 5)
Investor: Masaryk University